Loading…
Giant cell tumors of the sacrum—a nationwide study on midterm results in 26 patients after intralesional excision
Purpose Evaluation of recurrences, complications and function at mid-term follow-up after curettage for sacral giant cell tumor (GCT). Methods We retrospectively studied all 26 patients treated for sacral GCT in the Netherlands (from 1990 to 2010). Median follow-up was 98 (6–229) months. All patient...
Saved in:
Published in: | European spine journal 2014-09, Vol.23 (9), p.1949-1962 |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Purpose
Evaluation of recurrences, complications and function at mid-term follow-up after curettage for sacral giant cell tumor (GCT).
Methods
We retrospectively studied all 26 patients treated for sacral GCT in the Netherlands (from 1990 to 2010). Median follow-up was 98 (6–229) months. All patients underwent intralesional excision, 21 with local adjuvants, 5 radiotherapy, 3 IFN-α, 1 bisphosphonates. Functional outcome was assessed using Musculoskeletal Tumor Society (MSTS) score. Statistics were performed with Kaplan–Meier, Cox regression, log rank and Mann–Whitney
U
.
Results
Recurrence rate was 14/26 after median 13 (3–139) months and was highest after isolated curettage (4/5). Soft tissue masses >10 cm increased recurrence risk (HR = 3.3, 95 % CI = 0.81–13,
p
= 0.09). Complications were reported in 12/26 patients. MSTS was superior in patients without complications (27 vs. 21;
p
= 0.024).
Conclusion
Recurrence rate for sacral GCT was highest after isolated curettage, indicating that (local) adjuvant treatment is desired to obtain immediate local control. Complications were common and impaired function. |
---|---|
ISSN: | 0940-6719 1432-0932 |
DOI: | 10.1007/s00586-014-3263-5 |